A Clinical Trial comparing the effectiveness of pazopanib versus sunitinib in treating people with advanced kidney cancer.

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma - COMPARZ

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-002102-19-IE

Enrollment

927

Registered

2008-07-10

Start date

2008-11-24

Completion date

Unknown

Last updated

2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced and/or Metastatic Renal Cell Carcinoma MedDRA version: 14.1 Level: PT Classification code 10050513 Term: Metastatic renal cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: VOTRIENT Product Name: Pazopanib Product Code: GW786034 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Pazopanib CAS Number: 635702-64-6 Current Sponsor code: GW786034 Other

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 532 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 395

Exclusion criteria

Exclusion criteria: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. This study remains open to allow subjects currently on treatment continued access to their treatment (as determined by the investigator). No new subjects will be entered.

Design outcomes

Primary

Measure	Time frame
Main Objective: This Phase III study, VEG108844, has met and reported its primary and key secondary efficacy and safety objectives. An updated OS analysis is planned with a data cut-off of 30 September 2013. The study is being kept open beyond the completion and reporting of the primary and key secondary objectives to enable subjects currently on treatment with pazopanib or sunitinib to have continued access to their treatment until the occurrence of unacceptable toxicity, disease progression (as determined by the investigator), or other reason for withdrawal from treatment, and to discontinue collection of many studyspecific assessments. ;Secondary Objective: This Phase III study, VEG108844, has met and reported its primary and key secondary efficacy and safety objectives. An updated OS analysis is planned with a data cut-off of 30 September 2013. The study is being kept open beyond the completion and reporting of the primary and key secondary objectives to enable subjects currently on treatment with pazopanib or sunitinib to have continued access to their treatment until the occurrence of unacceptable toxicity, disease progression (as determined by the investigator), or other reason for withdrawal from treatment, and to discontinue collection of many studyspecific assessments. ;Primary end point(s): Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. ;Timepoint(s) of evaluation of this end point: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported.	—

Measure

Time frame

Main Objective: This Phase III study, VEG108844, has met and reported its primary and key secondary efficacy and safety objectives. An updated OS analysis is planned with a data cut-off of 30 September 2013. The study is being kept open beyond the completion and reporting of the primary and key secondary objectives to enable subjects currently on treatment with pazopanib or sunitinib to have continued access to their treatment until the occurrence of unacceptable toxicity, disease progression (as determined by the investigator), or other reason for withdrawal from treatment, and to discontinue collection of many studyspecific assessments. ;Secondary Objective: This Phase III study, VEG108844, has met and reported its primary and key secondary efficacy and safety objectives. An updated OS analysis is planned with a data cut-off of 30 September 2013. The study is being kept open beyond the completion and reporting of the primary and key secondary objectives to enable subjects currently on treatment with pazopanib or sunitinib to have continued access to their treatment until the occurrence of unacceptable toxicity, disease progression (as determined by the investigator), or other reason for withdrawal from treatment, and to discontinue collection of many studyspecific assessments. ;Primary end point(s): Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. ;Timepoint(s) of evaluation of this end point: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported.

—

Secondary

Measure	Time frame
Secondary end point(s): Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. ;Timepoint(s) of evaluation of this end point: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported.	—

Measure

Time frame

Secondary end point(s): Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported. ;Timepoint(s) of evaluation of this end point: Section deemed no longer required and removed from the protocol by amendment No 5 (please refer to Section 11 the Appendix 7 of the protocol amendment No 5). Enrolment is complete and the study has been reported.

—

Countries

Australia, Canada, China, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Taiwan, United Kingdom, United States

Contacts

Public ContactClinical Trials Helpdesk

GlaxoSmithKline Research & Development Ltd

GSKClinicalSupportHD@gsk.com+44 0208 990 44 66

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026